Innate Pharma presents proprietary antibody-drug conjugate technology at the World ADC Summit in San Francisco
Innate Pharma appoints Nicolai Wagtmann Chief Scientific Officer
Financial results for the first half of 2013
Innate Pharma announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Annual General Meeting of June 28, 2013
Number of shares and voting rights of Innate Pharma as at May 17, 2013
Innate pharma to hold its annual general meeting of shareholders on june 28, 2013, in Marseille, France
Innate Pharma announces 1Q2013 revenue and cash in line with expectations
Innate Pharma presents new data for proprietary programs targeting TLR3 and KIR3DL2
